Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy

Molecular Therapy

Volumn 19, Issue 9, 2011, Pages 1619-1625

  Yao, Xinglei ^a,b   Yoshioka, Yasuo ^a   Morishige, Tomohiro ^a   Eto, Yusuke ^a   Narimatsu, Shogo ^a   Kawai, Yasuaki ^a   Mizuguchi, Hiroyuki ^a,c   Gao, Jian Qing ^b   Mukai, Yohei ^a   Okada, Naoki ^a   Nakagawa, Shinsaku ^a  

^a OSAKA UNIVERSITY   (Japan)

^b ZHEJIANG UNIVERSITY   (China)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD31 ANTIGEN; HERPES SIMPLEX VIRUS THYMIDINE KINASE; MACROGOL; PENTAPEPTIDE; PEPTIDE POLYETHYLENE GLYCOL CONJUGATED ADENOVIRUS VECTOR; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC GENE THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER GENE THERAPY; CANCER INHIBITION; CANCER TISSUE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; GENE; GENE EXPRESSION; HERPES SIMPLEX VIRUS THYMIDINE KINASE GENE; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; LIVER; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIMARY TUMOR; SYSTEMIC THERAPY; TISSUE DISTRIBUTION; TRANSGENE; TUMOR MODEL; TUMOR VASCULARIZATION; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; WOUND HEALING IMPAIRMENT;

ADENOVIRIDAE; SIMPLEXVIRUS;

EID: 80052399280     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.112     Document Type: Article

References (44)

1. Mizuguchi, H and Hayakawa, T (2004). Targeted adenovirus vectors. Hum Gene Ther 15: 1034-1044 (Pubitemid 39552285)
2. Eto, Y, Yoshioka, Y, Mukai, Y, Okada, N and Nakagawa, S (2008). Development of PEGylated adenovirus vector with targeting ligand. Int J Pharm 354: 3-8 (Pubitemid 351400325)
3. Horowitz, J (1999). Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications. Curr Opin Mol Ther 1: 500-509 (Pubitemid 29420047)
4. Vattemi, E and Claudio, PP (2006). Adenoviral gene therapy in head and neck cancer. Drug News Perspect 19: 329-337 (Pubitemid 44409884)
5. Gabrilovich, DI (2006). INGN 201 (Advexin): adenoviral p53 gene therapy for cancer. Expert Opin Biol Ther 6: 823-832 (Pubitemid 44174214)
6. Kim, S, Peng, Z and Kaneda, Y (2008). Current status of gene therapy in Asia. Mol Ther 16: 237-243 (Pubitemid 351168031)
7. Alemany, R, Suzuki, K and Curiel, DT (2000). Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 81(Pt 11): 2605-2609
8. Koizumi, N, Mizuguchi, H, Sakurai, F, Yamaguchi, T, Watanabe, Y and Hayakawa, T (2003). Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR-and alphav integrin-binding ablation. J Virol 77: 13062-13072 (Pubitemid 37494302)
9. Koizumi, N, Yamaguchi, T, Kawabata, K, Sakurai, F, Sasaki, T, Watanabe, Y et al. (2007). Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production. J Immunol 178: 1767-1773 (Pubitemid 46154648)
10. Gao, JQ, Eto, Y, Yoshioka, Y, Sekiguchi, F, Kurachi, S, Morishige, T et al. (2007). Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J Control Release 122: 102-110 (Pubitemid 47284554)
11. Wortmann, A, Vöhringer, S, Engler, T, Corjon, S, Schirmbeck, R, Reimann, J et al. (2008). Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol Ther 16: 154-162
12. Hofherr, SE, Shashkova, EV, Weaver, EA, Khare, R and Barry, MA (2008). Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther 16: 1276-1282 (Pubitemid 351866059)
13. Kreppel, F and Kochanek, S (2008). Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 16: 16-29
14. Yao, X, Yoshioka, Y, Morishige, T, Eto, Y, Watanabe, H, Okada, Y et al. (2009). Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis. Gene Ther 16: 1395-1404
15. Yoshioka, Y, Tsutsumi, Y, Nakagawa, S and Mayumi, T (2004). Recent progress on tumor missile therapy and tumor vascular targeting therapy as a new approach. Curr Vasc Pharmacol 2: 259-270 (Pubitemid 38855032)
16. Ryan, SM, Mantovani, G, Wang, X, Haddleton, DM and Brayden, DJ (2008). Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin Drug Deliv 5: 371-383 (Pubitemid 351721718)
17. Iyer, AK, Khaled, G, Fang, J and Maeda, H (2006). Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 11: 812-818 (Pubitemid 44280021)
18. Lanciotti, J, Song, A, Doukas, J, Sosnowski, B, Pierce, G, Gregory, R et al. (2003). Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol Ther 8: 99-107 (Pubitemid 36939301)
19. Ogawara, K, Rots, MG, Kok, RJ, Moorlag, HE, Van Loenen, AM, Meijer, DK et al. (2004). A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther 15: 433-443 (Pubitemid 38639615)
20. Eto, Y, Gao, JQ, Sekiguchi, F, Kurachi, S, Katayama, K, Maeda, M et al. (2005). PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med 7: 604-612 (Pubitemid 40744526)
21. Menezes, KM, Mok, HS and Barry, MA (2006). Increased transduction of skeletal muscle cells by fibroblast growth factor-modified adenoviral vectors. Hum Gene Ther 17: 314-320
22. Ogawara, K, Kuldo, JM, Oosterhuis, K, Kroesen, BJ, Rots, MG, Trautwein, C et al. (2006). Functional inhibition of NF-kappaB signal transduction in alphavbeta3 integrin expressing endothelial cells by using RGD-PEG-modified adenovirus with a mutant IkappaB gene. Arthritis Res Ther 8: R32
23. Jung, Y, Park, HJ, Kim, PH, Lee, J, Hyung, W, Yang, J et al. (2007). Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells. J Control Release 123: 164-171 (Pubitemid 47570000)
24. Park, JW, Mok, H and Park, TG (2008). Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus. Biochem Biophys Res Commun 366: 769-774
25. Morrison, J, Briggs, SS, Green, N, Fisher, K, Subr, V, Ulbrich, K et al. (2008). Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol Ther 16: 244-251 (Pubitemid 351168032)
26. Folkman, J (2007). Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286 (Pubitemid 46505878)
27. Ellis, LM and Hicklin, DJ (2008). VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591
28. Zurita, AJ, Arap, W and Pasqualini, R (2003). Mapping tumor vascular diversity by screening phage display libraries. J Control Release 91: 183-186 (Pubitemid 37288889)
29. Hajitou, A, Pasqualini, R and Arap, W (2006). Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 16: 80-88
30. Hoffman, JA, Giraudo, E, Singh, M, Zhang, L, Inoue, M, Porkka, K et al. (2003). Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 4: 383-391 (Pubitemid 37491099)
31. Mäkelä, AR, Matilainen, H, White, DJ, Ruoslahti, E and Oker-Blom, C (2006). Enhanced baculovirus-mediated transduction of human cancer cells by tumor-homing peptides. J Virol 80: 6603-6611 (Pubitemid 43927462)
32. Mok, H, Palmer, DJ, Ng, P and Barry, MA (2005). Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 11: 66-79 (Pubitemid 40012000)
33. Yoshioka, Y, Asavatanabodee, R, Eto, Y, Watanabe, H, Morishige, T, Yao, X et al. (2008). Tat conjugation of adenovirus vector broadens tropism and enhances transduction efficiency. Life Sci 83: 747-755
34. Mu, Y, Kamada, H, Kodaira, H, Sato, K, Tsutsumi, Y, Maeda, M et al. (1999). Bioconjugation of laminin-related peptide YIGSR with polyvinyl pyrrolidone increases its antimetastatic effect due to a longer plasma half-life. Biochem Biophys Res Commun 264: 763-767
35. Hanahan, D and Folkman, J (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364 (Pubitemid 26272076)
36. Kaneda, Y, Tsutsumi, Y, Yoshioka, Y, Kamada, H, Yamamoto, Y, Kodaira, H et al. (2004). The use of PVP as a polymeric carrier to improve the plasma half-life of drugs. Biomaterials 25: 3259-3266 (Pubitemid 38234786)
37. Doronin, K, Shashkova, EV, May, SM, Hofherr, SE and Barry, MA (2009). Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther 20: 975-988
38. Liu, Y and Deisseroth, A (2006). Tumor vascular targeting therapy with viral vectors. Blood 107: 3027-3033
39. Mathis, JM, Stewart, PL, Zhu, ZB and Curiel, DT (2006). Advanced generation adenoviral virotherapy agents embody enhanced potency based upon CARindependent tropism. Clin Cancer Res 12: 2651-2656
40. Li, Y, Pong, RC, Bergelson, JM, Hall, MC, Sagalowsky, AI, Tseng, CP et al. (1999). Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 59: 325-330 (Pubitemid 29048862)
41. Neri, D and Bicknell, R (2005). Tumour vascular targeting. Nat Rev Cancer 5: 436-446 (Pubitemid 40791486)
42. Mizuguchi, H and Kay, MA (1998). Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 9: 2577-2583 (Pubitemid 29004630)
43. Mizuguchi, H and Kay, MA (1999). A simple method for constructing E1-and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 10: 2013-2017 (Pubitemid 29387915)
44. Yao, X, Yoshioka, Y, Eto, Y, Morishige, T, Okada, Y, Mizuguchi, H et al. (2007). TERT promoter-driven adenovirus vector for cancer gene therapy via systemic injection. Biochem Biophys Res Commun 362: 419-424 (Pubitemid 47332425)